Nuvation Bio Inc (NYSE:NUVB) Share Price

Company Profile

Business description
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Contact
1500 Broadway
Suite 1401
New YorkNY10036
USA
T: +1 332 208-6102
https://www.nuvationbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
305

Recommended

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.

Jacob Robbins | 21 September 2026

Morningstar analysts’ take on the takeover for this undervalued industrial player.

Esther Holloway | 20 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,919.10	3.60	-0.04%
CAC 40	8,142.08	77.06	0.96%
DAX 40	25,573.66	269.60	1.07%
Dow JONES (US)	51,886.95	204.31	0.40%
FTSE 100	10,737.18	78.05	0.73%
HKSE	25,042.71	291.93	1.18%
NASDAQ	26,951.40	428.86	1.62%
Nikkei 225	65,018.95	882.70	1.38%
NZX 50 Index	13,821.20	82.06	0.60%
S&P 500	7,729.11	78.61	1.03%
S&P/ASX 200	8,731.90	0.70	0.01%
SSE Composite Index	3,949.91	38.04	0.97%